Neurodegenerative diseases are a common cause of morbidity and cognitive impairment in
older adults. Most clinicians who care for the elderly are not trained to diagnose these …

Neuroimaging has made it possible to measure pathological brain changes associated with
Alzheimer's disease (AD) in vivo. Over the past decade, these measures have been …

For the last decade, it has been shown that neuroimaging can be a potential tool for the
diagnosis of Alzheimer's Disease (AD) and its prodromal stage, Mild Cognitive Impairment …

Accurate and early diagnosis of Alzheimer's disease (AD) plays important role for patient
care and development of future treatment. Structural and functional neuroimages, such as …

Alzheimer disease (AD) originally meant a disorder of early-onset (EOAD;< 65 years of age)
and did not include older patients with “senile dementia.” In fact, the first patient reported …

Summary Background Three subtypes of Alzheimer's disease (AD) have been
pathologically defined on the basis of the distribution of neurofibrillary tangles: typical AD …

Mild cognitive impairment (MCI), particularly the amnestic subtype (aMCI), is considered as
a transitional stage between normal aging and a diagnosis of clinically probable Alzheimer's …

Objective To develop a visual rating scale for posterior atrophy (PA) assessment and to
analyse whether this scale aids in the discrimination between Alzheimer's disease (AD) and …

The high-dimensional pattern classification methods, eg, support vector machines (SVM),
have been widely investigated for analysis of structural and functional brain images (such as …

Purpose: To examine regional cerebral blood flow (rCBF) in incident mild cognitive
impairment (MCI) and Alzheimer disease (AD) by using continuous arterial spin-labeling …